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 Th e discovery that circulating anti-DNA 
antibodies are a diagnostic feature of pa-
tients with systemic lupus erythematosus 
helped defi ne the disease (reviewed by 
Foster  et al. 1 ). Anti bodies against double-
stranded DNA are relatively specifi c, and 
the presence of other auto antibodies (for 
example, anti-SmRNP) provides further 
diagnostic support. Initial correlation of 
serum autoantibody levels with disease 
activity in some patients led to the notion 
that these antibodies were pathogenic, 
and this was supported by the fi nding 
that high-affi  nity, anti-DNA antibodies 
were present in the kidney eluates of lupus 
patients. However, it turned out that these 
and other correlations were inconsistent 
and of limited clinical utility in predict-
ing either the type of nephritis or disease 
severity in individual patients. 2 In this 
regard, distinguishing pathogenic from 
non-pathogenic antibodies has been dif-
fi cult, and interpretation is further mud-
dled by diverse clinical manifestations 
among patients. Not only does organ in-
volvement vary, but during the course of 
a person ’ s lifetime, organs can be involved 
variably and diff erentially. 3 In one sense, 
the kidney represents a microcosm of 
systemic manifestations, with a varying 
spectrum of lesions involving glomeruli, 
larger vessels, and tubules. Furthermore, 
the spectrum of glomerular involve-
ment is considerable, from only immune 
depo sits without pathologic or clinical 
evidence of disease, to crescentic glomer-
ulonephritis, accompanied by severe inter-
stitial and vascular infl ammation, with 
rapidly progressive renal failure. Never-
theless, in human lupus, the quantity and 
location of glomerular immune depo sits 
generally correlate with the class and 
severity of nephritis. 1,3 Many factors con-
tribute to pathogenesis; however, immune 
deposit formation is critical. Th erefore, 
what makes lupus autoantibodies form 
immune deposits is crucial to deciphering 
the disease process. 
 Keys to understanding autoantibody 
pathogenicity have been, in part, derived 
from analysis of inbred murine strains 
that spontaneously develop lupus. Some 
strains develop severe nephritis, whereas 
others do not. Comparison of serum anti-
bodies among lupus strains, along with 
analysis of IgG eluted from the kidneys of 
nephritic mice, revealed that the eluted 
antibodies were more broadly reactive 
than the serum antibodies, in that they 
reacted and crossreacted with multiple 
autoantigens, including cell-surface, 
matrix, and basement membrane anti-
gens. 1,4 By contrast, serum autoantibodies 
were more restricted with specificity 
directed at DNA and nucleoproteins, and 
they were not crossreactive. Comparisons 
in human lupus provided similar fi nd-
ings. 5 A partial explanation for this cross-
reactivity was that the seemingly diverse 
antigens shared epitopes, although 
induced fi t may also play a role. Although 
this does not explain autoantibodies with 
reactivity to glomerular antigens, per se, 
collectively the fi ndings suggest that anti-
gen binding is relevant to pathogenesis in 
general, and immune deposit formation 
in particular. 
 Evaluation of the pathogenicity of mono-
clonal autoantibodies derived from lupus-
prone mice and lupus patients provided 
additional insights. Aft er injection into 
normal mice, some anti-DNA antibodies 
produced immune deposits and nephritis, 
whereas others did not. 6,7 Th e pathogenic 
antibodies were typically IgG and more 
crossreactive, much like those eluted from 
the nephritic kidneys. It is particularly 
noteworthy that, among the pathogenic 
subset, the location of immune deposits 
formed varied with the individual anti-
bodies. Strikingly, this was especially 
apparent when antibodies from diff erent 
laboratories were compared. For example, 
some formed predominantly subendo-
thelial deposits, whereas others formed 
mesangial deposits, and others were more 
like cryoglobulins. Furthermore, inde-
pendent analysis revealed that lupus 
autoantibodies that shared encoding V 
gene sequences, derived from diff erent 
mice and diff erent strains, produced sim-
ilar pathologies. 8 – 10 Moreover, autoanti-
bodies derived from lupus-prone mice 
that were encoded by sequences similar to 
those encoding pathogenic anti-DNA 
antibodies, but that did not bind to DNA, 
bound to glomerular autoantigens (for 
example, laminin) and produced patho-
logies similar to those produced by 
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 Although lupus autoantibodies provide diagnostic value, discordance 
between serum levels and nephritis poses mechanistic questions. 
Krishnan and co-workers report that only those that crossreact with 
basement membrane components produce immune deposits. Thus, 
other glomerular binding properties probably define where deposits 
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disease expression. Clearly other factors determine the ultimate 
phenotype; however, the findings provide insights into the variable 
disease patterns in lupus nephritis. 
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the nephritogenic anti-DNA antibodies. 1 
Collectively the fi ndings suggested that 
specific antigen-binding properties of 
the autoantibodies mediated immune 
deposit formation by direct binding 
to glomerular antigens, and that these 
specifi cities infl uenced both the location 
of immune deposits formed and subse-
quent pathology ( Figure 1 ). 
 Other mechanisms of immune deposit 
formation have been proposed. 11,12  In situ 
immune deposit formation of nucleo-
somes and autoantibodies has been sug-
gested to occur by initial charge – charge 
interaction of positively charged nucleo-
somes with negatively charged constitu-
ents in the basement membrane (for 
example, heparan sulfate), with subse-
quent binding of either anti-DNA anti-
bodies or anti-nucleosome antibodies to 
antigenic components within the exposed 
nucleosome (for example, DNA). Immune 
deposit formation in this manner seems 
feasible; however, overt nephritis by this 
mechanism has not been demonstrated. 
 Krishnan and co-workers 13 (this issue) 
further address the relevance of these 
 in situ mechanisms by comparing the 
immune deposit-forming capacity of 
related anti-DNA antibodies, but with dif-
ferent relative affinities for basement 
membrane constituents. Th ey fi nd that 
only anti-DNA antibodies that bind to 
components of the basement membrane 
form immune deposits, activate comple-
ment, and induce proteinuria. Further-
more, they observe the presence of 
autoantibodies alone within the deposits, 
without other chromatin material, further 
supporting the direct binding mechanism. 
Th is is consistent with previous observa-
tions demonstrating pathogenicity of 
lupus autoantibodies via direct inter-
actions with glomerular antigens. Th ey 
clearly defi ne this as a major mechanism 
of immune deposit formation in lupus 
nephritis. 
 However, this is probably the tip of 
the iceberg in terms of disease-relevant 
antigens in lupus nephritis. Seek, and 
ye shall fi nd. Many antigenic specifi cities 
for autoantibodies have been observed 
in individuals with lupus, and these 
specifi cities contribute to disease vari-
ability. Anti-DNA antibodies represent a 
signifi cant fraction of deposited immu-
noglobulins, but the larger fraction of 
immunoglobulins eluted from nephritic 
kidneys do not bind to DNA. 4,5,14 In this 
regard, we observed that monoclonal 
lupus autoantibodies with glomerular 
binding properties (for example, versus 
laminin) are encoded by genes encoding 
anti-DNA antibodies, suggesting that they 
have common origins. Importantly, the 
results indicate that other direct binding 
activities are relevant to pathogenesis. 15 
Th e fi ndings also indicate that in a given 
person with lupus, the dominant autoan-
tigen-binding profi le, at a given point in 
time, determines whether and where 
immune deposits will form. Th is probably 
explains the relative lack of correlation of 
either anti-DNA levels or circulating 
immune complex levels with disease activ-
ity. Th e phenomena also contribute to the 
diversity of lesions observed among 
patients. 
 Th e  in situ mechanism involving so-
called  ‘ planted antigens ’ in the kidney, 
with subsequent autoantibody binding, 
probably amplifi es disease, as with bind-
ing of anti-nucleosome antibodies to 
nucleosomes or of anti-IgG to deposited 
IgG (that is, by rheumatoid factors). In 
this context, antibody binding to fi xed 
glomerular antigens,  in situ , provides an 
ideal scaff old for subsequent FcR engage-
ment and local complement activation 
that is necessary for amplification of 
infl ammation. 16 
 Th e results of Krishnan  et al. 13 clarify 
previous discrepancies. Local immune 
deposit formation has been observed to 
be critical for initiating nephritis in other 
experimental models and human disease. 
Preformed, circulating immune com-
plexes do not appear to play a major role 















 Figure 1  |  Immune deposit formation in systemic lupus erythematosus. Antibodies (Y-like 
stick figures) bind to the glomerular basement membrane (GBM) or glomerular cells to initiate 
immune deposit formation. Krishnan and co-workers 13 demonstrate autoantibody binding to 
GBM constituents, whereas others have demonstrated binding to glomerular cells per se. These 
local interactions initiate FcR engagement and complement activation that, in turn, lead to 
inflammation, proteinuria, and / or reduced glomerular filtration rate. Soluble circulating immune 
complexes engage FcR on glomerular cells (for example, mesangial, center of figure), leading to 
further cellular activation, amplifying disease. The antigenic specificity of autoantibodies against 
GBM and cell-surface antigens determines the location of immune deposits, and the quantity and 
site of immune deposits influence phenotypic expression and severity of disease. Variability in 
antigen specificities and IgG isotype of pathogenic antibodies among individuals contributes to 
differences in disease expression. 
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accord with clinical observations that 
dissociate immune complex levels from 
disease severity. Furthermore, it is consis-
tent with similar mechanisms in other 
antibody-dependent experimental auto-
immune models and human nephritis, 
where disease is dependent on either local 
immune complex format ion or 
antigen-specific cellular responses. In 
lupus, antigenic specifi city is essential, and 
direct binding of autoantibodies is key to 
pathogenesis. Th is principle helps explain 
variable organ involvement in lupus 
patients. Th us, although systemic lupus 
erythematosus is characterized by multi-
organ involvement and the presence 
of circulating anti-DNA antibodies, 
the autoantigens that autoantibodies 
react with are crucial to where deposits 
form. Th is defi nes organ involvement in 
an individual patient. In the context of 
nephritis, the capacity of autoantibodies 
to bind to glomerular antigens determines 
and infl uences the quality and intensity of 
disease activity. In one sense, the kidney 
represents a microcosm of the organism, 
with variable disease depending on the 
antigenic specificity in a given lupus 
patient. Whereas anti-erythrocyte anti-
bodies lead to hemolytic anemia, anti-
neuronal antibodies produce cerebritis, 
and autoantibodies that react with renal 
antigens initiate nephritis of one type 
and / or another. 
 Once immune deposits form, the 
capacity of the deposited antibodies to 
engage FcR and activate complement 
infl uences disease severity. Th ereaft er, 
other mechanisms may be operative in 
amplifying immune deposit formation, 
with loss of tolerance via neoantigen 
exposure, binding of anti-IgG, and so on. 
Nevertheless, the results of Krishnan and 
co-workers 13 provide conclusive evidence 
that the initial events are mediated by 
autoantibody binding to glomerular anti-
gens. Th ey demonstrate this for anti-DNA 
antibodies. In this context it is likely that 
other autoantibodies / autoantigens are 
involved in the process. Although anti-
DNA antibodies constitute a signifi cant 
fraction of deposited IgG, at most, they 
represent less than half of the deposited 
IgG. Individual observations of autoanti-
body binding to various renal antigens 
contribute, and these specifi cities infl u-
ence the variable disease process. The 
particular specifi city that dominates in a 
given individual probably aff ects disease 
expression. 
 Is that all there is? Defi nitely not. Both 
B cells and T cells themselves actively 
participate in various stages of disease, 
and macrophages play a major role. Th e 
intensity of the infl ammatory and fi bro-
genic responses is crucial to severity, and 
this is determined by the autoimmune 
response, the systemic inflammatory 
response, and the kidney ’ s response to the 
assault. Nevertheless, in addition to clari-
fying the major mechanism of immune 
deposit formation in lupus nephritis, the 
results of Krishnan and co-workers 13 raise 
questions pertaining to the functional 
consequences of antigen ligation, per se, 
during the disease process. Does ligation 
interfere with properties associated with 
fi ltration? With normal cell – cell interac-
tions? With cell – matrix interactions? 
With normal repair processes and events? 
A more precise understanding of the par-
ticipants and mechanisms involved in the 
disease process should lead to better 
means to monitor disease activity. 
 If confi rmed in human lupus, the results 
have implications for both biomarker 
development and therapy. More refi ned 
biomarkers using glomerular cell-surface 
antigens and glomerular matrix proteins 
have the potential to define when the 
kidney-specifi c, autoimmune response is 
active. Timing immunosuppressive therapy 
to this window in patients with nephritis 
would help defi ne when to initiate immuno-
suppressive therapy and when to limit its 
use. Th is would be especially helpful to 
improve reversibility, reduce fi brosis, and 
limit the toxic eff ects of immunosuppres-
sive therapy. Additionally, strategies might 
be devised that either eliminate or silence 
these particular B cells, limit autoreactive 
B cell – T cell interactions, or prevent nephri-
togenic antibodies from depositing. 
Although targeting anti-DNA antibodies 
was not successful, targeting either kidney-
specific autoantibodies or the specific 
population of T cells that activate them has 
the potential to limit disease with less toxi-
city. Validation of the fi ndings in human 
lupus should be particularly helpful. 
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